LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
$1.88
arrow_downward
-0.27%(-0.0050) 1D
$1.91
arrow_upward
+1.63% (+0.031)bedtimeAfter hours
Closed: Sep 30, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LXRX...
Open
$1.89
High
$1.95
Low
$1.84
Mkt. cap
834.29M
Avg. vol.
3.16M
Volume
0.00
52-wk high
$2.68
52-wk low
$1.10
EPS
-$0.15
Beta
1.36
Shares outstanding
444.96M
No. of employees
81
Open
$1.89
High
$1.95
Low
$1.84
Mkt. cap
834.29M
Avg. vol.
3.16M
Volume
0.00
52-wk high
$2.68
52-wk low
$1.10
EPS
-$0.15
Beta
1.36
Shares outstanding
444.96M
No. of employees
81
News stories
From web sources and news partners
Seeking Alpha
·
13 hours ago
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Currently.com
·
2 days ago
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
StreetInsider
·
2 days ago
Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Investing.com
·
2 days ago
Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc